|
SI2511297T1
(sl)
|
2004-02-06 |
2015-07-31 |
Morphosys Ag |
Proti -CD38 humana protitelesa in njihova uporaba
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
US20060030003A1
(en)
*
|
2004-05-12 |
2006-02-09 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
US20050255120A1
(en)
*
|
2004-05-12 |
2005-11-17 |
Simon Michael R |
Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
|
|
US20050260214A1
(en)
*
|
2004-05-12 |
2005-11-24 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
US20110117088A1
(en)
*
|
2004-05-12 |
2011-05-19 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
|
US20110110937A1
(en)
*
|
2004-05-12 |
2011-05-12 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
|
SG10201912554TA
(en)
|
2005-03-23 |
2020-02-27 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
|
TW200745162A
(en)
*
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
CN103554260A
(zh)
|
2005-10-12 |
2014-02-05 |
莫佛塞斯公司 |
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
|
|
US20070106233A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Percutaneous Systems, Inc. |
Systems and methods for dilating and accessing body lumens
|
|
JP5328018B2
(ja)
*
|
2006-06-05 |
2013-10-30 |
国立大学法人広島大学 |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
US20100150941A1
(en)
*
|
2006-09-13 |
2010-06-17 |
Dso National Laboratories |
Hemagglutinin antibody and uses thereof
|
|
PL2081595T3
(pl)
|
2006-09-26 |
2019-11-29 |
Genmab As |
Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
|
|
EP2191840A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2191843A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
EP2191842A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191841A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
KR101827048B1
(ko)
|
2010-08-27 |
2018-02-07 |
길리아드 바이오로직스, 인크. |
매트릭스 메탈로프로테이나제 ９에 대한 항체
|
|
BR112013006769B1
(pt)
|
2010-09-27 |
2021-02-02 |
Morphosys Ag |
combinação sinérgica
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
CA2865501A1
(en)
|
2012-02-29 |
2013-09-06 |
Gilead Biologics, Inc. |
Antibodies to matrix metalloproteinase 9
|
|
GB201216002D0
(en)
*
|
2012-09-07 |
2012-10-24 |
Deutsches Rheuma Forschungszentrum Berlin Drfz |
Compositions adn methods
|
|
PL2900232T3
(pl)
|
2012-09-25 |
2018-05-30 |
Morphosys Ag |
Kombinacje i ich zastosowania
|
|
ES2621377T3
(es)
|
2012-11-05 |
2017-07-03 |
Morphosys Ag |
Anticuerpo marcado radiactivamente y usos del mismo
|
|
CN112851769A
(zh)
|
2014-01-27 |
2021-05-28 |
分子模板公司 |
用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
CN113831416A
(zh)
|
2014-06-11 |
2021-12-24 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
EA035979B1
(ru)
|
2014-09-09 |
2020-09-08 |
Янссен Байотек, Инк. |
Варианты комбинированной терапии анти-cd38 антителами
|
|
KR102597989B1
(ko)
|
2014-12-04 |
2023-11-02 |
얀센 바이오테크 인코포레이티드 |
급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
|
|
KR20170110601A
(ko)
|
2015-02-05 |
2017-10-11 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
|
|
PL3294769T3
(pl)
|
2015-05-13 |
2021-07-05 |
Morphosys Ag |
Leczenie szpiczaka mnogiego (mm)
|
|
IL319936A
(en)
*
|
2015-05-20 |
2025-05-01 |
Janssen Biotech Inc |
Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
|
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
|
WO2016209921A1
(en)
|
2015-06-22 |
2016-12-29 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
EP4516319A3
(en)
|
2015-11-03 |
2025-05-07 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
CA3007031A1
(en)
|
2015-12-01 |
2017-06-08 |
Genmab B.V. |
Anti-death receptor antibodies and methods of use thereof
|
|
JP7362250B2
(ja)
|
2016-03-04 |
2023-10-17 |
モルフォシス・アーゲー |
多発性骨髄腫におけるｍタンパク質反応の臨床評価
|
|
KR102557126B1
(ko)
|
2016-12-07 |
2023-07-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자
|
|
ES2971981T3
(es)
|
2017-01-25 |
2024-06-10 |
Molecular Templates Inc |
Moléculas de reconocimiento de células que comprenden efectores de la subunidad A de la toxina Shiga desinmunizados y epítopos de células T CD8+
|
|
MA50514A
(fr)
|
2017-10-31 |
2020-09-09 |
Janssen Biotech Inc |
Méthodes de traitement du myélome multiple à haut risque
|
|
US20230158070A1
(en)
|
2018-01-30 |
2023-05-25 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
CN109265551B
(zh)
*
|
2018-09-25 |
2020-09-15 |
华东师范大学 |
Cd38抗体、嵌合抗原受体和药物
|
|
AU2019395841B2
(en)
|
2018-12-14 |
2025-02-27 |
Morphosys Ag |
Antibody formulations
|
|
CN113574071B
(zh)
|
2019-03-15 |
2025-03-25 |
莫佛塞斯公司 |
用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
|
|
AU2020298572A1
(en)
|
2019-07-02 |
2021-11-18 |
Fred Hutchinson Cancer Center |
Recombinant Ad35 vectors and related gene therapy improvements
|
|
TW202235435A
(zh)
|
2021-01-14 |
2022-09-16 |
德商莫菲西斯公司 |
抗cd38抗體及其用途
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|